RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Antiangiogenesis Therapy with Bevacizumab Improves Survival in Metastatic or Relapsed Cervical Cancer
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 12
OP 13
DO 10.1177/155989771306005
UL http://mdc.sagepub.com/content/13/6/12.abstract
AB Bevacizumab (BEV) is the first targeted agent that when added to standard chemotherapy improved overall survival (OS) in women with metastatic or relapsed cervical cancer. This finding from a randomized, open-label Phase 3 study represents the first instance in which a targeted therapy has significantly prolonged survival in this setting. This article discusses the The Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer study of the Gynecological Oncology Group [GOG 240; NCT00803062; Tewari KS et al. J Clin Oncol 2013 (suppl; abstr 3)].